AbCellera Biologics Inc. Amortization of Intangible Assets
AbCellera Biologics Inc. (ABCL) reported Amortization of Intangible Assets of $1.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- AbCellera Biologics Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $931.00K, a 0.22% increase year-over-year.
- AbCellera Biologics Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $920.00K, a 0.22% decline year-over-year.
- AbCellera Biologics Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $909.00K.
- AbCellera Biologics Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $940.00K, a 97.16% decline year-over-year.
- AbCellera Biologics Inc. amortization of intangible assets for fiscal 2025 was $3.70M, a 74.13% decline from fiscal 2024.
- AbCellera Biologics Inc. amortization of intangible assets for fiscal 2024 was $14.30M, a 23.28% increase from fiscal 2023.
- AbCellera Biologics Inc. amortization of intangible assets for fiscal 2023 was $11.60M, a 10.48% increase from fiscal 2022.
- AbCellera Biologics Inc. amortization of intangible assets for fiscal 2022 was $10.50M, a 3.96% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $931.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.85M 10-Q · filed 2026-08-05 | $2.76M derived: sum of 3 quarters · filed 2026-08-05 | $3.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $920.00K 10-Q · filed 2026-05-11 | $1.83M derived: sum of 2 quarters · filed 2026-05-11 | $2.77M derived: sum of 3 quarters · filed 2026-05-11 | $3.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.85M derived: sum of 2 quarters · filed 2026-02-24 | $2.78M derived: sum of 3 quarters · filed 2026-08-05 | $3.70M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $940.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.87M derived: sum of 2 quarters · filed 2026-08-05 | $2.79M 10-Q · filed 2025-11-06 | -$50.76M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $929.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.85M 10-Q · filed 2026-08-05 | -$51.70M derived: sum of 3 quarters · filed 2026-08-05 | -$18.61M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $922.00K 10-Q · filed 2026-05-11 | -$52.63M derived: sum of 2 quarters · filed 2026-05-11 | -$19.54M derived: sum of 3 quarters · filed 2026-05-11 | $13.53M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$53.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$20.46M derived: sum of 2 quarters · filed 2026-02-24 | $12.61M derived: sum of 3 quarters · filed 2026-02-24 | $14.30M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $33.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $66.16M derived: sum of 2 quarters · filed 2025-11-06 | $67.85M 10-Q · filed 2025-11-06 | $71.46M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $33.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.76M 10-Q · filed 2025-08-07 | $38.38M derived: sum of 3 quarters · filed 2026-02-24 | $41.05M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $1.69M 10-Q · filed 2025-05-08 | $5.30M derived: sum of 2 quarters · filed 2026-02-24 | $7.97M derived: sum of 3 quarters · filed 2026-02-24 | $10.63M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.29M derived: sum of 2 quarters · filed 2026-02-24 | $8.94M derived: sum of 3 quarters · filed 2026-02-24 | $11.60M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.33M derived: sum of 2 quarters · filed 2023-11-02 | $7.99M 10-Q · filed 2023-11-02 | $10.64M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.31M 10-Q · filed 2023-08-03 | $7.97M derived: sum of 3 quarters · filed 2025-02-27 | $10.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.66M 10-Q · filed 2024-05-07 | $5.31M derived: sum of 2 quarters · filed 2025-02-27 | $7.94M derived: sum of 3 quarters · filed 2025-02-27 | $10.55M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.29M derived: sum of 2 quarters · filed 2025-02-27 | $7.89M derived: sum of 3 quarters · filed 2025-02-27 | $10.50M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.24M derived: sum of 2 quarters · filed 2023-11-02 | $7.84M 10-Q · filed 2023-11-02 | $10.51M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | $2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.21M 10-Q · filed 2023-08-03 | $7.88M derived: sum of 3 quarters · filed 2024-02-20 | $10.38M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | $2.61M 10-Q · filed 2023-05-04 | $5.27M derived: sum of 2 quarters · filed 2024-02-20 | $7.78M derived: sum of 3 quarters · filed 2024-02-20 | $10.24M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $5.17M derived: sum of 2 quarters · filed 2024-02-20 | $7.63M derived: sum of 3 quarters · filed 2024-02-20 | $10.10M 10-K · filed 2024-02-20 | $10.06M 10-K · filed 2022-02-25 |
| 2021-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.97M derived: sum of 2 quarters · filed 2022-11-08 | $7.43M 10-Q · filed 2022-11-08 | $9.11M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.93M 10-Q · filed 2022-08-09 | $6.61M derived: sum of 3 quarters · filed 2023-02-21 | ||
| 2021-03-31 | $2.46M 10-Q · filed 2022-05-10 | $4.14M derived: sum of 2 quarters · filed 2023-02-21 | |||
| 2020-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $2.50M 10-K · filed 2023-02-21 | $2.52M 10-K · filed 2022-02-25 | ||
| 2020-09-30 | $821.00K 10-Q · filed 2021-11-10 | ||||
| 2020-03-31 | $158.00K 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |